(April 25, 2022, 1:10 PM EDT) -- ALEXANDRIA, Va. — In an April 21 petition for inter partes review (IPR) filed with the Patent Trial and Appeal Board, Abbott Diabetes Care Inc. maintains that six claims of a biointerface patent should be canceled for inadequate written description or, alternatively, as obvious in view of prior art....